Recovery of Therapeutically Ablated Engineered Blood‐Vessel Networks on a Plug‐and‐Play Platform

Abstract

AbstractLimiting the availability of key angiogenesis‐promoting factors is a successful strategy to ablate tumor‐supplying blood vessels or to reduce excessive vasculature in diabetic retinopathy. However, the efficacy of such anti‐angiogenic therapies (AATs) varies with tumor type, and regrowth of vessels is observed upon termination of treatment. The ability to understand and develop AATs remains limited by a lack of robust in vitro systems for modeling the recovery of vascular networks. Here, complex 3D micro‐capillary networks are engineered by sequentially seeding human bone marrow‐derived mesenchymal stromal cells and human umbilical vein endothelial cells (ECs) on a previously established, synthetic plug‐and‐play hydrogel platform. In the tightly interconnected vascular networks that form this way, the two cell types share a basement membrane‐like layer and can be maintained for several days of co‐culture. Pre‐formed networks degrade in the presence of bevacizumab. Upon treatment termination, vessel structures grow back to their original positions after replenishment with new ECs, which also integrate into unperturbed established networks. The data suggest that this plug‐and‐play platform enables the screening of drugs with blood‐vessel inhibiting functions. It is believed that this platform could be of particular interest in studying resistance or recovery mechanisms to AAT treatment.